[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI1373230T1 - Enantioselektivna sinteza azetidinonskih intermediatnih spojin - Google Patents

Enantioselektivna sinteza azetidinonskih intermediatnih spojin

Info

Publication number
SI1373230T1
SI1373230T1 SI200230193T SI200230193T SI1373230T1 SI 1373230 T1 SI1373230 T1 SI 1373230T1 SI 200230193 T SI200230193 T SI 200230193T SI 200230193 T SI200230193 T SI 200230193T SI 1373230 T1 SI1373230 T1 SI 1373230T1
Authority
SI
Slovenia
Prior art keywords
intermediate compounds
enantioselective synthesis
azetidinone intermediate
azetidinone
compound
Prior art date
Application number
SI200230193T
Other languages
English (en)
Inventor
Xiaoyong Fu
Timothy L Mcallister
T K Thiruvengadam
Chou-Hong Tann
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of SI1373230T1 publication Critical patent/SI1373230T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI200230193T 2001-03-28 2002-03-25 Enantioselektivna sinteza azetidinonskih intermediatnih spojin SI1373230T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27928801P 2001-03-28 2001-03-28
EP02728561A EP1373230B1 (en) 2001-03-28 2002-03-25 Enantioselective synthesis of azetidinone intermediate compounds
PCT/US2002/009123 WO2002079174A2 (en) 2001-03-28 2002-03-25 Enantioselective synthesis of azetidinone intermediate compounds

Publications (1)

Publication Number Publication Date
SI1373230T1 true SI1373230T1 (sl) 2005-12-31

Family

ID=23068350

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230193T SI1373230T1 (sl) 2001-03-28 2002-03-25 Enantioselektivna sinteza azetidinonskih intermediatnih spojin

Country Status (29)

Country Link
US (1) US6627757B2 (sl)
EP (1) EP1373230B1 (sl)
JP (1) JP4145663B2 (sl)
KR (1) KR100590342B1 (sl)
CN (1) CN1275949C (sl)
AT (1) ATE305459T1 (sl)
AU (1) AU2002258605B2 (sl)
BG (1) BG66189B1 (sl)
BR (1) BRPI0208384B1 (sl)
CA (1) CA2442219C (sl)
CZ (1) CZ304929B6 (sl)
DE (1) DE60206365T2 (sl)
DK (1) DK1373230T3 (sl)
EA (1) EA006898B1 (sl)
EE (1) EE05453B1 (sl)
ES (1) ES2245733T3 (sl)
HK (1) HK1057546A1 (sl)
HR (1) HRP20030760B1 (sl)
HU (1) HU230229B1 (sl)
IL (2) IL157552A0 (sl)
MX (1) MXPA03008803A (sl)
NZ (1) NZ527852A (sl)
PL (1) PL205952B1 (sl)
RS (1) RS50386B (sl)
SI (1) SI1373230T1 (sl)
SK (1) SK287408B6 (sl)
UA (1) UA75644C2 (sl)
WO (1) WO2002079174A2 (sl)
ZA (1) ZA200306612B (sl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
EP1699759B1 (en) 2003-12-23 2010-10-20 AstraZeneca AB Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
JP4590417B2 (ja) * 2004-01-16 2010-12-01 メルク・シャープ・エンド・ドーム・コーポレイション Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法
WO2006039334A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
US7700597B2 (en) 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists
US8308559B2 (en) * 2007-05-07 2012-11-13 Jay Chun Paradise box gaming system
TW200726746A (en) 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
CA2608108A1 (en) * 2005-05-09 2006-11-16 Microbia, Inc. Organometal benzenephosphonate coupling agents
CN101218213A (zh) * 2005-05-11 2008-07-09 迈克罗比亚公司 制备酚类4-联苯基氮杂环丁烷-2-酮的方法
KR20080025077A (ko) * 2005-05-25 2008-03-19 마이크로비아 인코포레이티드 4-(비페닐일)아제티딘-2-온 포스폰산의 제조방법
JP2008546784A (ja) * 2005-06-20 2008-12-25 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
KR20070063592A (ko) * 2005-09-08 2007-06-19 테바 파마슈티컬 인더스트리즈 리미티드 에제티밉의 합성을 위한 중간체인(3ｒ,4ｓ)-4-((4-벤질옥시)페닐)-1-(4-플루오로페닐)-3-((ｓ)-3-(4-플루오로페닐)-3-히드록시프로필)-2-아제티디논의제조 방법
HU0501164D0 (en) * 2005-12-20 2006-02-28 Richter Gedeon Vegyeszet New industrial process for the production of ezetimibe
CA2637565A1 (en) 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
US7956182B2 (en) * 2006-02-16 2011-06-07 Kotobuki Pharmaceutical Co., Ltd. Process for preparing optically active alcohols
US7910698B2 (en) * 2006-02-24 2011-03-22 Schering Corporation NPC1L1 orthologues
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
JP2010502702A (ja) * 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
US20090047716A1 (en) * 2007-06-07 2009-02-19 Nurit Perlman Reduction processes for the preparation of ezetimibe
CA2692268A1 (en) * 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as cb1 antagonists
JP2010531874A (ja) * 2007-06-28 2010-09-30 インターベット インターナショナル ベー． フェー． Ｃｂ１アンタゴニストとしての置換ピペラジン
WO2009032264A1 (en) * 2007-08-30 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing intermediates of ezetimibe by microbial reduction
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
WO2010025085A2 (en) 2008-08-29 2010-03-04 Codexis, Inc. Ketoreductase polypeptides for the stereoselective production of (4s)-3[(5s)-5(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
WO2010113175A2 (en) 2009-04-01 2010-10-07 Matrix Laboratories Ltd Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
US9102959B2 (en) 2009-08-19 2015-08-11 Codexis, Inc. Ketoreductase polypeptides for the preparation of phenylephrine
US9040262B2 (en) 2010-05-04 2015-05-26 Codexis, Inc. Biocatalysts for ezetimibe synthesis
WO2012155932A1 (en) 2011-05-17 2012-11-22 Pharmathen S.A. Improved process for the preparation of ezetimibe
CN111518046B (zh) * 2020-06-04 2022-04-15 中山奕安泰医药科技有限公司 依泽替米贝中间体及依泽替米贝的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2046823A1 (de) 1970-09-23 1972-03-30 Farbwerke Hoechst AG vormals Meister Lucius & Brüning, 6000 Frankfurt Neue Azetidinone-(2) und Verfahren zu deren Herstellung
JPS5628057A (en) 1979-08-13 1981-03-19 Isuzu Motors Ltd Front cab suspension device for tiltable cab
DE3006193C2 (de) 1980-02-19 1984-04-12 Siemens AG, 1000 Berlin und 8000 München Elektrische Anschlußverbindung der Elektroden eines Gasentladungs-Überspannungsableiters
US4680391A (en) 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
JPS61121479A (ja) 1984-11-19 1986-06-09 Mitsubishi Electric Corp 太陽電池素子
JPS61180212A (ja) 1985-02-06 1986-08-12 Asahi Optical Co Ltd 後絞り型写真レンズ
JPS62219681A (ja) 1986-03-20 1987-09-26 Toshiba Corp 光信号処理素子の基準光源
ZA877398B (en) 1986-10-03 1989-05-30 Lilly Co Eli 7-((meta-substituted)phenylglycine)1-carba-1-dethiacephalosporins
US4803266A (en) 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
EP0333268A1 (en) 1988-03-18 1989-09-20 Merck & Co. Inc. Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone
NZ228600A (en) 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
US4952689A (en) 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
US4876365A (en) 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
FR2640621B1 (fr) 1988-12-19 1992-10-30 Centre Nat Rech Scient N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
IL99658A0 (en) 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
JPH04356195A (ja) 1991-05-30 1992-12-09 Kyowa Hakko Kogyo Co Ltd アゼチジノン誘導体の製造法
US5561227A (en) 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
JP2525125B2 (ja) 1991-07-23 1996-08-14 シェリング・コーポレーション 血清コレステロ―ル低下薬として有用な置換β−ラクタム化合物およびそれらの製法
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
EP0707567B1 (en) 1993-07-09 2001-09-12 Schering Corporation Process for the synthesis of azetidinones
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5631635A (en) * 1995-05-08 1997-05-20 Motorola, Inc. Message/response tracking system and method for a two-way selective call receiving device
US5618707A (en) 1996-01-04 1997-04-08 Schering Corporation Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
KR100311554B1 (ko) 1995-10-31 2002-06-20 둘락 노먼 씨. 콜레스테롤저하제로유용한슈가-치환된2-아제티디논
WO1997016424A1 (en) 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
EP0865429A1 (en) 1995-12-08 1998-09-23 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis
CZ341098A3 (cs) 1996-04-26 1999-03-17 Smithkline Beecham Plc Azetidinonové deriváty pro ošetřování aterosklerózy
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
GB9611947D0 (en) 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
WO1998001119A2 (en) 1996-07-09 1998-01-15 Merck & Co., Inc. Pharmaceutical compositions comprising simvastatin
EP0930882A2 (en) 1996-08-02 1999-07-28 Institut Pasteur De Lille Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
US6242439B1 (en) 1997-10-07 2001-06-05 Boehringer Ingelheim (Canada) Ltd. Azetidinone derivatives for the treatment of HCMV infections
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
DE69925862T2 (de) 1998-12-07 2006-05-04 Schering Corp. Verfahren zur herstellung von azetidinonen
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
AU3382699A (en) 1999-04-05 2000-10-23 Schering Corporation Stereoselective microbial reduction for the preparation of - (4-fluorophenyl) - 3(r)-(3(s) - hydroxy-3 (4-fluorophenyl) propyl))-4(s) (4-hydroxyphenyl)-2-azetidinone
WO2000063703A1 (en) 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
PT1347987E (pt) 2000-12-20 2005-01-31 Schering Corp 2-azetidinonas substituidas com acucar uteis como agentes hipocolesterolemicos
CZ20031732A3 (cs) 2000-12-21 2003-09-17 Aventis Pharma Deutschland Gmbh 1,2-Difenylazetidinony a farmaceutické prostředky s jejich obsahem k léčení poruch metabolismu lipidů
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same

Also Published As

Publication number Publication date
CN1500083A (zh) 2004-05-26
RS50386B (sr) 2009-12-31
CZ304929B6 (cs) 2015-01-28
YU74803A (sh) 2006-05-25
BR0208384A (pt) 2004-06-15
DE60206365T2 (de) 2006-07-06
KR100590342B1 (ko) 2006-06-15
HRP20030760A2 (en) 2004-08-31
BG66189B1 (bg) 2011-12-30
CA2442219C (en) 2007-09-11
NZ527852A (en) 2005-03-24
MXPA03008803A (es) 2004-02-18
US6627757B2 (en) 2003-09-30
BRPI0208384B1 (pt) 2016-05-31
ZA200306612B (en) 2004-10-12
DK1373230T3 (da) 2005-11-07
HK1057546A1 (en) 2004-04-08
PL363864A1 (en) 2004-11-29
HUP0303526A3 (en) 2004-11-29
IL157552A0 (en) 2004-03-28
ES2245733T3 (es) 2006-01-16
UA75644C2 (en) 2006-05-15
KR20030085573A (ko) 2003-11-05
ATE305459T1 (de) 2005-10-15
HUP0303526A2 (hu) 2004-01-28
JP2004532210A (ja) 2004-10-21
DE60206365D1 (de) 2005-11-03
EP1373230B1 (en) 2005-09-28
EE200300464A (et) 2003-12-15
PL205952B1 (pl) 2010-06-30
BG108168A (en) 2004-09-30
CN1275949C (zh) 2006-09-20
SK11862003A3 (sk) 2004-04-06
HRP20030760B1 (en) 2011-07-31
AU2002258605B2 (en) 2006-01-12
EA200300970A1 (ru) 2004-04-29
EE05453B1 (et) 2011-08-15
SK287408B6 (sk) 2010-09-07
WO2002079174A3 (en) 2003-02-27
CA2442219A1 (en) 2002-10-10
EA006898B1 (ru) 2006-04-28
JP4145663B2 (ja) 2008-09-03
IL157552A (en) 2009-08-03
WO2002079174A2 (en) 2002-10-10
CZ20032610A3 (en) 2004-03-17
HU230229B1 (hu) 2015-10-28
EP1373230A2 (en) 2004-01-02
US20020193607A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
IL157552A0 (en) Enantioselective synthesis of azetidinone intermediate compounds
AU2003282983A1 (en) Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
BG106340A (en) Substituted oxoazaheterocyclyl compounds
IL173377A0 (en) Compounds for the treatment of metabolic disorders
MXPA05012268A (es) N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa.
IL163607A0 (en) Amino-substituted 2,6-dialkoxystyryl 4-substitutedbenzylsulfones for treating proliferative disorders
FI960095A0 (fi) Menetelmä atsetidinonien syntetitoimiseksi
GB0021421D0 (en) Compounds
MY138263A (en) Therapeutic chroman compounds
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
IL156768A0 (en) Process for preparing (+/-) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
GB9920959D0 (en) Novel process
MXPA03001272A (es) Procedimiento para la preparacion de dinapsolina.
MXPA04004980A (es) Antagonistas del receptor ccr-3.
AU2002212241A1 (en) Method for producing chiral compounds
GEP20084343B (en) Use of indole derivatives for the treatment of neuropathic pain
AU2001253602A1 (en) Synthesis of intermediates useful in preparing tricyclic compounds
YU40599A (sh) Mikrobna biotransformacija
HU0001287D0 (en) New intermediate and process for its production
ES2097688A1 (es) Hexahidroazepinonas y tetrahidrobenzazepinonas sustituidas.